Takeda spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants

HilleVax's stock took a nosedive after the vaccine biotech’s sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis (AGE).

The virus-like particle-based vaccine, dubbed HIL-214, missed all primary and secondary endpoints of the NEST-IN1 study of more than 2,800 infants aged about five months of age in the U.S. and Latin America.